June 8-11, 2020 | San Diego, CA


Double Helix Sponsor


Schedule at a glance

Registration Rates

Join the Mailing List

BioProcess Theater 2018
Print Schedule


BioProcess Theater Logo


*Open to all attendees

Tuesday, June 5 - Thursday, June 7

Since 2008, the BPI Theater, a live, interactive amphitheater located at the heart of the BioProcess Zone (booth #375), provides biopharmaceutical professionals with a dedicated destination to meet, network, listen and learn about the latest scientific, technology, business, and financial trends impacting biopharmaceutical research, development, and manufacturing.

 In 2018, this live, three-day, complimentary event consists of targeted panel discussions and individual presentations focusing on: 

Emerging Therapies: Cell & Gene Therapies, Viral Vectors/Vaccines, Manufacturing Strategies for Therapeutic Modalities, Capacity Challenges & Opportunities

Emerging Techniques & Technologies: Drug Product Supply Challenges, Speed to Market, Capacity vs. Cost, SUS vs, Stainless, Analytics & Formulation, Single-Use Bioprocessing

Tuesday, June 5


BioProcess Insider Daily- One-on-One Live Executive Interviews 
10:00 am - 11:00 am

10:00 – 10:15am Dave Kenyon, Senior Director, Global Scientific and Technical Affairs, Patheon Biologics
10:15 – 10:30am Kevin Noonan, Partner, McDonnell Boehnen Hulbert & Berghoff LLP
10:30 – 10:45am Rory Mullen, VP, New Business, IDA Ireland
10:45 – 11:00am Andy Topping, CSO, FUJIFILM Diosynth Biotechnologies

Manufacturing Automation for Patient-Scale Cell Therapies
11:00 am - 11:20 am
Speaker: Nina Bauer, Associate Director, Autologous Cell Therapy Commercial Development, Lonza Pharma & Biotech

Acoustic Cell Processing - An Innovation in Cell Therapy Manufacturing
11:20 am - 11:40 pm
Speaker: Richard Grant, Chief Product Officer, FloDesign

A Platform Production Process for Manufacturing Viral Vector and Vaccine Therapeutics Using Vero Cells
11:40 am - 12:00 pm

Speaker: Sandhya S Buchanan, Director, Upstream Process Development, FUJIFILM Diosynth Biotechnologies

Therapeutic Modalities - Business and Manufacturing Strategies Impacting the Decision to Develop One Therapy Type vs. Another
12:00 pm - 1:00 pm
Moderator: Patricia Seymour, Senior Consultant, BioProcess Technology Consultants, Inc.


  • John Lee, SVP, Pharmaceutical Development, decibel Therapeutics
  • Michael Kaufman, SVP, CMC, Mersana Therapeutics
  • Jennifer Michaelson, VP, Preclinical Research and Early Development, Cullinan Oncology
  • Weichang Zhou, SVP, CTO, WuXi Biologics

 Industry experts discuss different modalities to treat various diseases, their unique manufacturing challenges, and appropriate strategy decisions including:

  • Manufacturability
  • Access to Manufacturing Capacity - outsource or build
  • 20/20 - How prevalent will these therapies be by 2020

Feeding the Demand for Cell and Gene Therapy Production
1:00 pm - 2:00 pm
Moderator: Dan Stanton, Editor, BioProcess Insider



  • Dr. David Brindley, University of Oxford and Harvard University
  • Ohad Karnieli, CEO and Co-Founder, Atvio Biotech, ISCT Process and Product Development Co-Chair


FDA Commissioner Scott Gottlieb described regenerative medicines as being ‘no longer the stuff of science fiction’ last year, and a spate of approvals of CAR T-cell and gene therapies seems to prove this.

With both Big Biopharma and biotech throwing scientists and funds towards these next-generation therapies, CDMOs have jumped upon the opportunity and invested in capacity and expertise.In this discussion, we speak with some of these third-parties and ask how they are supporting this lucrative area: What they can offer biopharma firms, what technologies and processing expertise they bring, and how they and how they can help industry navigate these relatively untrodden production and regulatory paths.

The Development of a Next Generation Antibody-Drug Conjugate (ADC)
2:00 pm - 2:20 pm
Speaker: Ken Meek, VP, Business Development and Marketing, MabPlex International Co., Ltd.



Wednesday June 6


BioProcess Insider Daily
10:15 am - 10:45 am

10:15 – 10:30am Patrick Lucy, CBO, Pfenex
10:30 – 10:45am Angus Turner, VP, WuXi Biologics

Rapid, Reliable Response to Biologic Drug Substance and Drug Product Supply Challenges
11:00 am - 11:20 am
Speaker: Scott Battist, VP, GM & Site Head – Drug Substance Plant & BJ Hull, VP, GM & Site Head – Drug Product Plant, Emergent Bio

Speed Matters – Gene to GMP in 9 Months
11:20 am – 11:40 am
Speaker: Igor Fisch, PhD., CEO, Selexis, SA

It’s All About Speed: Getting to Early-Development Clinical Trials Quickly
11:40 am – 12:00 pm
Speaker: David J. Kenyon, Sr. Director, Global Scientific and Technical Affairs, Patheon, part of Thermo Fisher Scientific

Using New Technologies to Compress Timelines, Increase Capacity, and Reduce Costs – Why, When and How
12:00 pm - 1:00 pm
Moderator: Tom Ransohoff, Vice President & Principle Consultant, BioProcess Technology Consultants, Inc. 


  • Rajesh Beri, Technical Director BioManufacturing, Research & Technology, Lonza Pharma & Biotech
  • Geoffrey Hodge, Chief Technical Officer, UNUM Therapeutics 
  • Chris Love, Professor, MIT
  • Jorg Thommes, Senior Vice President, Pharmaceutical Sciences & Technology, Visterra, Inc.

Industry experts discuss and explore the need for new technologies in our industry as well as the roles of academia, suppliers, end-users and consortia in the current adoption cycle.

Lessons learned in what works (and what doesn’t) will be shared along with potential strategies to improve new technology adoption practices in the future.

Capacity Strategies – The strategy Behind the Large Scale SUS vs. Stainless Steel Investment
1:00 pm - 2:00 pm

Moderator: Dan Stanton, Editor, BioProcess Insider



  • Weichang Zhou, SVP, CTO,WuXi Biologics
  • Jenifer Wheat, Head of Commercial Development for Mammalian Manufacturing, Lonza Pharma & Biotech
  • Roger Lias, President & CEO, Avid Bioservices
  • Jim Vogel, Founder and Director, The BioProcess Institute


Often heralded as a fundamental part of the ‘facility of the future,’ single-use is now a prevalent part of the bioprocessing space. But does this mean industry’s historic reliance on stainless steel and fixed facilities is over?

In this roundtable discussion, we discuss the wealth of investment in single-use equipment and flexible manufacturing solutions by CDMOs over the past few years and pit this against what looks like a resurgence in fixed-cost stainless steel plants from a certain group of biomanufacturers. How do these differing uses of resources feed Biopharma and Biotech’s clinical and commercial demands, and what financial and regulatory risks are CDMOs facing through their capacity choices?

Emerging Technologies & Strategies to Accelerate Process Development and Time to Market 

2:00 pm – 2:20 pm

Speaker: Gustavo Mahler, President & CEO, AGC Biologics

Future Proofing and Understanding Your Molecule with Contemporary Analytics and Formulation Approaches
2:20 pm – 2:40 pm
Speaker: Greg Adams, Senior Director, Global Analytical Strategy & Development, FUJIFILM Diosynth Biotechnologies

Thinking Outside the Bag: Utilizing Single-Use Technology to Drive Innovation at the Benchtop Scale
2:40 pm – 3:00 pm
Speaker: Cristy Botens, Product Manager, Bioprocessing, Distek

Bringing Biologic Products to Market Faster by Partnering with a Single Services Provider from Development Through Commercial Supply
3:00 pm – 3:20 pm
Speaker: Andrew Sandford, VP, Business Development, Catalent Biologics

Product Development through Commercial Production – Guiding Your Biologic from Start to Finish
3:20 pm – 3:40 pm

Speaker: Eunyoung Yang, Team Leader, CDO Business Development Team, Samsung Biologics 

The Perks and Pitfalls of a Single-Use Biopharmaceutical Facility
3:40 pm – 4:00 pm
Speaker: Sun Ra Bullins, Director of Manufacturing, Avid Bioservices 

CMO Fusion: Where Stainless Steel meets Disposable Technology
4:00 pm – 4:20 pm
Speaker: Molly McGlaughlin, Director, Strategy and Business Development and Jim Stout, Director, Process Science, BioVectra  



Thursday June 7

Lift While You Climb: Women In Bio (WIB) presents a panel of Boardroom Ready program graduates for a discussion on career ambitions and the path to a corporate board of directors seat.
11:00 am - 1:00 pm
Moderator: Kristi Sarno, Director, Strategic Analysis, Latham Biopharm Group, National President Emeritus of Women in Bio (WIB)

  • Marianne DeBacker, Vice President, JNJ 
  • Terri Matkovits, COO, ContraVir
  • Jane Wasman, President/General Counsel, Acorda 
  • Sofija Ovic, CEO, ProPhase
  • Rebecca Frey, COO, Cardurion Pharmaceuticals
  • Dominique Cote, VP and Head of Market Excellence, UCB
Thank you to our 2019 Sponsors

Double Helix Sponsors

Helix Sponsors

Premier Sponsors